Shelter Rock Management LLC Purchases New Stake in Eli Lilly and Company $LLY

Shelter Rock Management LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 474 shares of the company’s stock, valued at approximately $510,000. Eli Lilly and Company makes up 0.5% of Shelter Rock Management LLC’s investment portfolio, making the stock its 24th largest holding.

Other institutional investors also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the period. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. grew its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. Finally, Miller Global Investments LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $33,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LLY shares. Morgan Stanley restated an “overweight” rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 1st. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Finally, Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,220.37.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,066.59 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.00 trillion, a PE ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a 50-day moving average price of $942.87 and a two-hundred day moving average price of $1,003.77.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.